

# Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease

**Afsaneh Forood MD<sup>1</sup>, Reza Malekpour-Afshar MD<sup>2</sup>, Amin Mahdavi MD<sup>3</sup>**

## Original Article

### Abstract

**Background:** Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction (MI) with PAI-1 level. Opium addiction is one of the most important factors in causing MI and cardiovascular events. This is due to it causing imbalance between coagulation and anticoagulation factors in the blood. This study was designed and implemented to determine the levels of PAI-I in opium-addicted patients with coronary artery disease in comparison with non addicts.

**Methods:** In this case-control study, 160 patients with coronary heart disease (CHD), which was confirmed by angiography results, were enrolled. All of the patients had a medical history, their creatinine levels and lipid profile were evaluated, morphine urine test was performed, and after that a blood sample was taken to determine the levels of PAI-1. Thus, the 80 patients who had a positive morphine urine test result formed the case group, and the control group was constituted of the 80 patients with negative morphine test results. The two groups were matched.

**Findings:** Average level of PAI-1 in the control group was  $2.4 \pm 2.6$  and in the case group was  $8.8 \pm 9.1$  and it was statistically significant ( $P < 0.001$ ). The frequency of two vessel disease was higher in opium addicted patients than non-addicted patients and this was statistically significant ( $P = 0.030$ ). However, the frequency of single vessel and three vessel disease was the same in the two groups. The two groups had no differences in age, lipid profile, and creatinine level. Moreover, females are at a higher risk of high PAI-1 levels.

**Conclusion:** PAI-1 levels in opium addicted patients with CHD are higher than other patients. In these patients, the risk of atherosclerosis and MI is higher than normal.

**Keywords:** Opium addiction, Coronary heart disease, Plasminogen activator inhibitor-I (PAI-1)

**Citation:** Forood A, Malekpour-Afshar R, Mahdavi A. **Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease.** *Addict Health* 2014; 6(3-4): 119-26.

**Received:** 13.04.2014

**Accepted:** 21.06.2014

1- Assistant Professor, Physiology Research Center, Department of Cardiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

2- Associate Professor, Neuroscience Research Center, Department of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

3- Resident, Department of Cardiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

Correspondence to: Afsaneh Forood MD, Email: [afsanehforood144@gmail.com](mailto:afsanehforood144@gmail.com)

## Introduction

Plasminogen is an important factor in the internal fibrinolysis system and it is mainly synthesized in the liver and exists as inactivated form in plasma. It converts to its active form by plasminogen activator and causes decomposition of clots. In other words, it prevents the formation of intravascular thrombus. One way of inhibiting physiological fibrinolysis system is applied by plasminogen activator inhibitor-1 (PAI-1). In normal conditions balance exists between tissue plasminogen activators and plasminogen activator inhibitor-I.<sup>1,2</sup>

PAI-1 is a type of glycoprotein, and its gene is located on chromosome 7.<sup>3</sup> Moreover, its production is exacerbated by endothelial cells, hepatocytes, and fibroblasts in conditions such as local homeostasis and in the presence of endotoxin and cytokines.<sup>3</sup> This glycoprotein, with its inhibitory effect on plasminogen activator, prevents the formation of plasmin. In the early morning, PAI-1 levels naturally rise, but plasminogen activator levels do not change. It seems that during early morning, the activity of the fibrinolysis system reduces and intravascular thrombus formation tends to be high. Perhaps this is one of the main causes of heart attack during early mornings.<sup>4</sup>

Several studies have shown the relationship between levels of plasminogen activator inhibitor-1, and either stable or unstable coronary artery disease.<sup>5,6</sup> However, in patients with MI, there is a clear association between PAI-1 levels and patient response to treatment with fibrinolytic agents; this has been demonstrated in several studies.<sup>7</sup> PAI-1 level is influenced by several factors such as patients' age, renal insufficiency, systolic blood pressure, insulin resistance, obesity, and triglyceride levels; however, it is not associated with cholesterol levels and smoking.<sup>8</sup>

There is increasing evidence indicating the importance of the internal fibrinolysis system and particularly PAI-1 level in the progression of atherosclerosis and that inhibiting glycoproteins can inhibit the development of atherosclerosis or even treat it. Thus, there are wide ongoing activities for the invention of compounds that inhibit the function of PAI-1. Although there is still no available combination that is approved for clinical use in humans, promising progress has

been made in this field.<sup>9</sup> In recent years, opium addiction has been taken into account as a risk factor for coronary artery disease, MI, and complications after coronary artery bypass surgery (graft occlusion).<sup>10,11</sup> Based on the evidence, this effect may be caused by increased inflammatory mediators by opium and disruption of the balance between coagulation and anticoagulation factors.<sup>12</sup>

Despite evidence regarding the role of opium in the advancement of atherosclerosis, so far, no study has been performed on its effects on plasma PAI-1 levels. In addition, based on clinical experiences, addicted patients with MI showed weaker response to treatment with thrombolytic drugs. The risk of stent stenosis and MI was higher in addicts than non-addicts, which could be due to the adverse impact of opium on the fibrinolysis system. In addition, due to the prevalence of opium addiction among patients in Iran, it is necessary to know the role of opium addiction and the appropriate respond for the prevention and treatment of these patients. Therefore, this study examined the effects of opium addiction on serum levels of PAI-1 in patients with coronary artery disease. Thus, the specialists in the field of health and macro-health system planners are provided with the required knowledge to plan and treat these patients according to an appropriate clinical approach.

## Methods

This was a case-control study, conducted on patients with coronary artery disease who were hospitalized at Shafa Hospital affiliated to Kerman University of Medical Sciences, Iran. Patients who were undergoing coronary angiography and had over 70% stenosis in at least one coronary artery, an age of less than 65 years, body mass index below 30, and had no history of diabetes, kidney failure, liver disease, and hypertriglyceridemia. Despite the confounding effect of hypertension on PAI-1 levels, due to limited sample size, the patients with hypertension were not excluded from the study and its impact on the statistical analysis was considered. The case group consisted of opium addicts who had inhaled, ingested, or used opium as skewered stones or in the form of molasses, burnt, heroin, and etcetera, for at least three times a week for at least three consecutive years.

Patients who were not addicts, proven by their history and urine morphine strip test, were enrolled as control group.

Before entering the study, the researcher gave the necessary explanations regarding the goals and methods of the study to the patients or those accompanying them, and they were allowed to ask questions about the study. They were also assured that all information will remain confidential and unwillingness to participate in the study will not affect the normal process of treatment. Written informed consents were eventually obtained from all patients.

The patients' demographic data, including age, gender, height, weight, blood pressure, biochemical findings, and the history and amount of opium consumption, were recorded by the investigator in the data collection form. Angiographic films were reviewed by two physicians specializing in cardiovascular disease. Moreover, having coronary artery disease (70% stenosis in at least one coronary artery) was checked and recorded in the data collection form for each patient. Then, venous blood samples were taken from each patient in the morning of angiography after 12 hours fasting, and were kept for PAI-1 measurement in a temperature below 20 °C.

Finally, after collecting blood samples from all patients participating in the study, PAI-1 was measured by enzyme-linked immunosorbent assay (ELISA) kit (KHC3071 manufactured by Invitrogen®) and the data were entered into the data collection forms. All collected data were entered into SPSS for Windows (version 16, SPSS Inc., Chicago, IL, USA) for analysis and were analyzed by central frequency indicators and distribution, Student's t-test, and chi-square test. In order to remove the effects of confounding variables, single univariate and multivariate

regressions were used.

## Results

In the present study, 160 patients with coronary artery disease were included; 80 patients entered into the study group and 80 patients in the control group. Of these patients, 106 were males (66.3%) and 54 were females (33.8%). The overall mean age of the patients was  $53.8 \pm 6.2$ , and the youngest patient was 40 years old and the oldest was 65 years old. Demographic characteristics of the two groups, including age, gender, body mass index (BMI), fasting blood sugar, and blood fat index, are shown in table 1. In all the cases of the demographic characteristics, except male gender, in both groups the differences were not statistically significant ( $P > 0.050$ ).

The mean dosage used in the addicts group was  $6.7 \pm 3.5$ . Regarding the method of consumption of opium, 16 (20%) used it orally, 40 (50%) by inhalation, and 24 (30%) as skewer stone. Regarding the duration of addiction to opium, 1 patient (1.3%) had an addiction for three years, 5 patients (6.3%) between three to five years, and 74 patients (92.5%) for more than five years. Results of the involvement of coronary heart disease (CHD) in patients of both groups are shown in table 2. The patients of the case group, compared to the control group, had higher levels of involvement, which was two-vessel disease and was statistically significant ( $P = 0.030$ ).

Average PAI-1 in all patients was  $5.6 \pm 7.9$  ng/ml. This amount in the two groups of addicts and non-addicts was  $8.8 \pm 9.1$  and  $2.4 \pm 2.6$ , respectively, and this difference between the two groups of control and case was significant ( $P < 0.001$ ).

Due to the lack of normal distribution of amount of PAI-1, logarithm of the concentration of PAI-1 was used to compare the levels of this

**Table 1.** Demographic characteristics of the patients in both case and control groups

Variables	Addicts	Non-addicts	P
Age (year)	$54.0 \pm 6.4$	$53.6 \pm 5.9$	0.700
BMI ( $\text{kg}/\text{m}^2$ )	$26 \pm 2$	$26 \pm 2$	0.500
Gender [male (%)]	60	46	0.019
Triglycerides (mg/dl)	$131 \pm 24$	$138 \pm 26$	0.090
Creatinine (mg/dl)	$0.9 \pm 0.2$	$0.9 \pm 0.4$	0.560
FBS (mg/dl)	$102 \pm 11$	$101 \pm 12$	0.470
History of high blood pressure (%)	28	30	0.700

BMI: Body mass index; FBS: Fasting blood sugar

**Table 2.** Frequency of involvement of coronary artery disease in two case and control groups

Variables	Case group	Control group
	n (%)	
One vessel disease	22 (27.5)	42 (52.5)
Two vessel disease	46 (57.5)	26 (32.5)
Three vessel disease	12 (15.0)	12 (15.0)

enzyme in the two study groups. The mean level of PAI-1 in the addicts' group was  $0.7 \pm 0.49$  and in the case group was  $0.14 \pm 0.46$ , and this difference was statistically significant ( $P < 0.001$ ).

Using univariate linear regression model and logarithm of PAI-1 as the dependent variable, the impact of demographic and clinical variables on the level of PAI-1 were also examined. Based on these results there was a significant relationship between opium addiction and PAI-1 levels ( $P < 0.001$ ,  $\beta = 0.56$ ). The impact of these variables on the level of PAI-1, using this model, is shown in table 3.

With regard to the likely effect of confounding variables on the relationship between addiction and PAI-1 level, multivariate linear regression model was used to examine the effect of variables with a P value of less than 0.2 in the univariate method. In other words, the only variables that were entered into multivariate models were

variables that had a P value less than 0.2 in the univariate model. The results of this model showed that opium addiction was still significantly increasing the levels of PAI-1 ( $P < 0.001$ ,  $\beta = 0.522$ ). In this model, there was a significant relationship between female gender and level of this inhibitor ( $P < 0.001$ ). In other words, female gender was an independent risk factor for increased levels of PAI-1. Furthermore, between cigarette smoking and levels of this inhibitor, there was a significant boundary relationship ( $P = 0.058$ ). This means that smoking was determined as an independent risk factor for increasing the level of PAI-1. The related data are shown in table 4.

## Discussion

This study, which was conducted on opium addicted and non-addicted patients with CHD, showed that the serum levels of PAI-1 in patients with opium addiction was about four times that in non-addicted patients. PAI-1 serum levels were higher in addicted patients and had no relationship with the dosage used.

Today, the defects of fibrinolytic activity have been identified in the case of atherothrombotic vascular disease.<sup>13,14</sup> This flaw in the occurrence of

**Table 3.** The impact of demographic and clinical variables on PAI-1 index using univariate linear regression LOG (PAI-1)

Variables	B (Beta)	SE	P
Gender (female)	0.307	0.087	0.001
BMI ( $\text{kg}/\text{m}^2$ )	-0.033	0.018	0.066
Triglyceride (mg/dl)	0.000	0.002	0.923
Cholesterol (mg/dl)	-0.003	0.002	0.075
Smoking (pack/year)	0.180	0.094	0.058
CAD intensity	0.048	0.053	0.365
Opium addict or non-addict	0.522	0.625	< 0.001

BMI: Body mass index; CAD: Coronary artery disease; SE: Standard error

**Table 4.** Multivariate linear regression

Variables	B (Beta)	SE	P
Gender (female )	0.307	0.087	0.001
BMI ( $\text{kg}/\text{m}^2$ )	-0.033	0.018	0.066
Triglyceride (mg/dl)	0.000	0.002	0.923
Cholesterol (mg/dl)	-0.003	0.002	0.075
Smoking (pack/year)	0.180	0.094	0.058
CAD intensity	0.048	0.053	0.365
Opium addict or non-addict	0.522	0.625	< 0.001

BMI: body mass index; CAD: Coronary artery disease; SE: Standard error

diseases, such as myocardial infarction (MI) and stroke, has been proven. However, its relationship with atherosclerosis is not yet known.<sup>15,16</sup> In patients with cardiovascular disease, especially in patients with a history of MI or acute coronary syndrome (ACS), impaired fibrinolytic activity was observed at rest and after physical activity and this disorder was associated with increased levels of PAI-1 in blood.<sup>17,18</sup> In addition, PAI-1 activity in patients with diabetes mellitus with MI is very high.<sup>19</sup> Moreover, PAI-1 activity and very-low-density lipoprotein (VLDL), and triglyceride levels, respectively, had a positive and negative relationship with insulin sensitivity.<sup>20</sup> High levels of PAI-1 is considered as a predictive factor in the incidence of MI.<sup>21</sup>

Previous studies have shown that plasma fibrinogen levels in men with opium addiction are higher than men with CHD.<sup>12</sup> Studies have also showed a positive relationship between serum levels of fibrinogen and the incidence of MI.<sup>22,23</sup> It has also been shown that fibrinogen levels have increased the possibility of vessel lumen involvement.<sup>22</sup> Based on the findings of this study, the frequency of two-coronary vessel occlusion was increased in patients with addiction compared to non-addict patients, which confirmed the results of previous studies.<sup>24</sup> It Seems that with increased levels of fibrinogen and PAI-1 in patients addicted to opium, the rate of cardiac and cerebral artery occlusion also increased.

Some people and even a few doctors believe that opium can be effective in the prevention and mitigation of cardiovascular diseases and diabetes. In this study, it was shown that lipid variables and creatinine levels in both control and case groups had no difference, which was consistent with the results obtained from the study by Asgary et al.<sup>24</sup> However, in another study it was shown that morphine prescription increased levels of total cholesterol and LDL.<sup>25</sup> Other studies also showed that PAI-1 levels were higher in patients with diabetes mellitus than in other patients, and that morphine injection increased blood sugar levels, despite the public perception.<sup>26</sup> Therefore, it seems that opium addicted patients who have diabetes are at higher risk than other people. Presently, there has been no study to assess the level of PAI-1 in patients with opium addiction, and this study, for the first time, examined PAI-1 level among these patients.

Based on the findings of this study, female gender was a risk factor for increased PAI-1. Nevertheless, findings of the study by Sadeghian et al. showed that men with opium addiction were more at risk of heart disease than men with diabetes.<sup>27</sup> It seems that in patients addicted to opium, due to the constant lipid parameters in comparison to other individuals and because of the positive relationship of these parameters with PAI-1 levels, lipid levels were higher. The present study confirmed this result. Followed by the high levels of PAI-1 in patients with opium addiction, the incidence of coronary artery lumen occlusion and cerebrovascular and cardiovascular diseases were higher than in normal individuals, and the reason for this is not yet clear.<sup>28</sup>

Based on previous studies, regarding PAI-1 serum levels in patients who were obese, PAI-1 levels increased with increasing BMI.<sup>29</sup> In the findings of this study, there was no significant relationship between PAI-1 levels and BMI amount in the patients of control and case groups. It appears that due to the compatibility between case and control groups and having BMI of more than 26 among the patients, the PAI-1 levels increased with the same ratio. This theory was consistent with the study by Shimomura et al.<sup>30</sup>

Studies showed that among the blood lipids, including triglycerides and cholesterol, only increased cholesterol levels caused the increased expression of PAI-1 in patients.<sup>31</sup> In addition, other studies showed that increase in morphine consumption caused an increase in total cholesterol and LDL levels.<sup>25</sup> However, the findings of this study did not show a significant relationship between increased levels of cholesterol or triglyceride and increased expression of PAI-1. It appears that in patients with high cholesterol levels, increased expression of PAI-1 occurs to an extent, and high cholesterol alone cannot increase PAI-1 levels. The results of the study by Vaisanen et al. also showed that increased blood cholesterol as LDL, has only a small role in increasing plasminogen and PAI-1 of patients.<sup>32</sup>

Numerous studies on the role of smoking and increased levels of PAI-1 have shown that cigarette smoking increases the risk of heart attack. Smoking increases the risk of atherosclerosis and PAI-1, and causes MI.<sup>33</sup> The findings of this study showed that smoking marginally increased PAI-1 levels resulting in a marginal increase, and it appears that



although smoking increased PAI-1, it had a small role in increasing its amount in the body, this was consistent with the findings of the study by Scarabin et al.<sup>34</sup>

The limitations of this study were the lack of similarity between the gender of the participants of both groups and the impossibility of excluding patients with high blood pressure. It is recommended that these facts be considered in similar studies in the future.

### Conclusion

Based on the findings of the current study, it was

shown that in patients with opium addiction and CHD PAI-1 serum level was higher than other patients, and the extent of vascular occlusion and the risk of MI were higher than normal individuals.

### Conflict of Interests

The Authors have no conflict of interest.

### Acknowledgements

We would like to thank the Physiology Research Center and Cardiovascular Department of Kerman University of Medical Sciences.

### References

1. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. *J Thromb Haemost* 2009; 7(1): 4-13.
2. Marx PF, Verkleij CJ, Valls SM, Meijers JC. Recent developments in thrombin-activatable fibrinolysis inhibitor research. *Mini Rev Med Chem* 2009; 9(10): 1165-73.
3. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. *J Clin Invest* 1986; 77(1): 165-9.
4. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. *Chronobiol Int* 1991; 8(5): 336-51.
5. Hamsten A, Wiman B, de FU, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. *N Engl J Med* 1985; 313(25): 1557-63.
6. Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A, De Faire U, et al. Haemostatic function in myocardial infarction. *Br Heart J* 1986; 55(1): 58-66.
7. Roger Lijnen H, Collen DS. Impaired fibrinolysis and the risk for coronary heart disease. *Circulation* 1996; 94: 2052-4.
8. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. *Thromb Haemost* 1997; 78(1): 656-60.
9. Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). *Expert Opin Ther Pat* 2013; 23(7): 801-15.
10. Masoomi M, Ramezani MA, Karimzadeh H. The relationship of opium addiction with coronary artery disease. *Int J Prev Med* 2010; 1(3): 182-6.
11. Safaïi N, Kazemi B. Effect of opium use on short-term outcome in patients undergoing coronary artery bypass surgery. *General Thoracic and Cardiovascular Surgery* 2010; 58(2): 62-7.
12. Masoomi M, Nasri HR, Farajpour F. Comparison of plasma Fibrinogen level in Opium addict men with non-addict men. *J Kerman Univ Med Sci* 2001; 9(1): 27-31. [In Persian].
13. Koenig W. Haemostatic risk factors for cardiovascular diseases. *Eur Heart J* 1998; 19(Suppl C): C39-C43.
14. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. *Thromb Haemost* 1993; 70(1): 138-43.
15. Benza RL, Grenett HE, Bourge RC, Kirklin JK, Naftel DC, Castro PF, et al. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. *Circulation* 1998; 98(21): 2248-54.
16. Benza RL, Grenett H, Li XN, Reeder VC, Brown SL, Go RC, et al. Gene polymorphisms for PAI-1 are associated with the angiographic extent of coronary artery disease. *J Thromb Thrombolysis* 1998; 5(2): 143-50.
17. Warshofsky MK, Wasserman HS, Wang W, Teng P, Sciacca R, Apfelbaum M, et al. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. *Am J Cardiol* 1997; 80(2): 145-9.
18. Bavenholm P, de FU, Landou C, Efendic S, Nilsson J, Wiman B, et al. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. *Eur Heart J* 1998; 19(3): 402-10.
19. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. *Br Heart J* 1993; 69(3): 228-32.
20. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen

- activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. *Diabetologia* 1993; 36(9): 817-25.
21. Teger-Nilsson AC, Larsson PT, Hjemdahl P, Olsson G. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade. *Circulation* 1991; 84(6 Suppl): VI72-VI77.
22. Yan RT, Fernandes V, Yan AT, Cushman M, Redheuil A, Tracy R, et al. Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J* 2010; 160(3): 479-86.
23. Shacham Y, Leshem-Rubinow E, Ben AE, Rogowski O, Topilsky Y, Roth A, et al. Comparison of C-reactive protein and fibrinogen levels in patients having anterior wall ST-Segment elevation myocardial infarction with versus without left ventricular thrombus (from a primary percutaneous coronary intervention cohort). *Am J Cardiol* 2013; 112(1): 57-60.
24. Asgary S, Naderi GH, Soghraty M, Ahmady P, Shahrezaee JR. A study of plasma lipid peroxidation, lipids and blood sugar level in opium addicts compared with control group. *ARYA Atheroscler* 2005; 1(2): 72-4.
25. Bryant HU, Story JA, Yim GK. Morphine-induced alterations in plasma and tissue cholesterol levels. *Life Sci* 1987; 41(5): 545-54.
26. Ali BH. The effect of l-tyrosine on some anti-nociceptive and non-nociceptive actions of morphine in mice. *General Pharmacology: The Vascular System* 1995; 26(2): 407-9.
27. Sadeghian S, Graili P, Salarifar M, Karimi AA, Darvish S, Abbasi SH. Opium consumption in men and diabetes mellitus in women are the most important risk factors of premature coronary artery disease in Iran. *Int J Cardiol* 2010; 141(1): 116-8.
28. Sadr Bafghi SM, Rafiei M, Bahadorzadeh L, Namayandeh SM, Soltani MH, Andishmand A. Is opium addiction a risk factor for acute myocardial infarction? *Acta Medica Iranica* 2005; 43(3):218-22.
29. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. *JAMA* 1998; 279(18): 1445-51.
30. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med* 1996; 2(7): 800-3.
31. Herz J, Couthier DE, Hammer RE. Correction: LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. *Cell* 1993; 73(3): 428.
32. Vaisanen S, Baumstark MW, Penttila I, Bouchard C, Halonen P, Rankinen T, et al. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. *Thromb Haemost* 1997; 78(6): 1495-9.
33. Brunet L, Pai M, Davids V, Ling D, Paradis G, Lenders L, et al. High prevalence of smoking among patients with suspected tuberculosis in South Africa. *Eur Respir J* 2011; 38(1): 139-46.
34. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. *Thromb Haemost* 1998; 80(5): 749-56.

## تعیین سطح سرمی مهار کننده «فعال کننده پلاسمینوژن نوع یک» در بیماران مبتلا به بیماری عروق کرونر معتاد به تریاک

دکتر افسانه فرود<sup>۱</sup>، دکتر رضا ملک پور افشار<sup>۲</sup>، دکتر امین مهدوی<sup>۳</sup>

### مقاله پژوهشی

### چکیده

**مقدمه:** مهار کننده فعال کننده پلاسمینوژن نوع یک (Plasminogen activator inhibitor-1 یا PAI-1) نوعی گلیکوپروتئین است که با اثر مهار بر فعال کننده پلاسمینوژن، از تشکیل پلاسمین جلوگیری کرده و در نتیجه مانع از لیز شدن لخته در عروق می گردد. شواهد متعددی ارتباط بیماری عروق کرونر و همچنین پاسخ به داروهای فیبرینولیتیک در بیماران مبتلا به سکت قلبی را با سطح مهار کننده فعال کننده پلاسمینوژن نوع ۱ به اثبات رسانده اند. اعتیاد به تریاک یکی از عوامل مهم در ایجاد سکت های قلبی و حوادث عروقی قلبی- مغزی است و این امر می تواند ناشی از نقش تریاک در بر هم زدن تعادل بین شاخص های انعقادی و ضد انعقادی باشد. این مطالعه با هدف تعیین سطح PAI-1 در بیماران معتاد به تریاک مبتلا به بیماری عروق کرونر طراحی و اجرا گردید.

**روش ها:** مطالعه حاضر به صورت مورد- شاهده بر روی ۱۶۰ بیمار مبتلا به بیماری عروقی قلب که با آنژیوگرافی نتایج آن ها تأیید شده بود، صورت پذیرفت. پس از بررسی نمودن سطح شاخص های چربی و کراتینین و تست مورفین ادرار، از تمام بیماران یک نمونه خون جهت بررسی سطح سرمی PAI-1 گرفته شد. بیمارانی که نتیجه مورفین ادرار مثبت داشتند، وارد گروه مورد و بیماران با تست منفی مورفین ادرار وارد گروه شاهد و دو گروه با یکدیگر همسان سازی شدند.

**یافته ها:** میانگین سطح سرمی مهار کننده فعال کننده پلاسمینوژن نوع یک در گروه شاهد  $2/6 \pm 2/4$  و در گروه مورد  $8/8 \pm 9/1$  نانوگرم در میلی لیتر و از نظر آماری معنی دار بود ( $P < 0/001$ ). همچنین بیماران معتاد به تریاک دارای انسداد عروقی با تعداد رگ بیشتر بودند که از نظر آماری معنی دار بود ( $P = 0/030$ ). از نظر شاخص های چربی، کراتینین و سن بیماران تفاوت آماری معنی داری وجود نداشت، تنها در بیماران جنس زن سطح مهار کننده فعال کننده پلاسمینوژن نوع یک بیشتر بود.

**نتیجه گیری:** سطح سرمی PAI-1 در معتادان به تریاک دچار بیماری عروقی قلب نسبت به سایر بیماران بیشتر و به دنبال آن میزان انسداد عروقی و خطر بروز انفارکتوس قلبی نیز بیشتر از افراد عادی می باشد.

**واژگان کلیدی:** اعتیاد به تریاک، بیماری عروقی قلب، فعال کننده پلاسمینوژن نوع یک

**ارجاع:** فرود افسانه، ملک پور افشار رضا، مهدوی امین. تعیین سطح سرمی مهار کننده «فعال کننده پلاسمینوژن نوع یک» در بیماران مبتلا به بیماری عروق کرونر معتاد به تریاک. مجله اعتیاد و سلامت ۱۳۹۳؛ ۶ (۳-۴): ۱۱۹-۱۲۶.

تاریخ پذیرش: ۹۳/۳/۳۱

تاریخ دریافت: ۹۳/۱/۲۴

۱- استادیار، مرکز تحقیقات فیزیولوژی، گروه قلب و عروق، دانشکده پزشکی، دانشگاه علوم پزشکی کرمان، کرمان، ایران

۲- دانشیار، مرکز تحقیقات علوم اعصاب، گروه پاتولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی کرمان، کرمان، ایران

۳- دستیار، گروه قلب و عروق، دانشکده پزشکی، دانشگاه علوم پزشکی کرمان، کرمان، ایران

Email: afsanehforood144@gmail.com

نویسنده مسؤول: دکتر افسانه فرود